xamoterol has been researched along with sulpiride in 3 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (sulpiride) | Trials (sulpiride) | Recent Studies (post-2010) (sulpiride) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 4,152 | 427 | 635 |
| Protein | Taxonomy | xamoterol (IC50) | sulpiride (IC50) |
|---|---|---|---|
| Carbonic anhydrase 1 | Homo sapiens (human) | 1.2 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.019 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0858 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.2651 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.2215 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.62 | |
| D(2) dopamine receptor | Canis lupus familiaris (dog) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for xamoterol and sulpiride
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |